1 / 8

Introduction to a WHO Model List of Essential In Vitro Diagnostics (the EDL)

Introduction to a WHO Model List of Essential In Vitro Diagnostics (the EDL). WHO Department of Essential Medicines and Health Products. Adriana Velazquez Berumen | Senior advisor on medical devices, EMP, Geneva. www.who.int. 13 December 2018. Context of the EDL.

klaw
Download Presentation

Introduction to a WHO Model List of Essential In Vitro Diagnostics (the EDL)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Introduction to a WHO Model List of Essential In Vitro Diagnostics (the EDL) WHO Department of Essential Medicines and Health Products • Adriana Velazquez Berumen | Senior advisor on medical devices, EMP, Geneva • www.who.int • 13 December 2018

  2. Context of the EDL • WHO recognises that in vitro diagnostics (IVDs) are an essential component to: • Advance universal health coverage • Address health emergencies • Promote healthier populations • The three strategic priorities of the WHO Thirteenth General Programme of Work (2019-2023). Source: Image from iStock.com

  3. Objectives of the EDL • The EDL sets out a group of IVDs that are recommended by WHO for use at various levels of a tiered laboratory network • The EDL is expected to: • Provide evidence-based guidance to countries for the development of local essential IVD lists • Inform countries, United Nations (UN) agencies and other stakeholders who support regulation, selection, procurement, supply, donations or provision of IVDs • Provide guidance to the medical technology private sector on IVD priorities needed to address global health issues Source: Image from iStock.com

  4. Benefits of an EDL • Support countries to prioritize their testing and infrastructure needs • Support outbreak preparedness • Facilitate the development of high priority new IVDs by industry and funders • Availability of IVDs will ensure safe and rational use of medicines in the EMLs • Increase affordability by facilitating coordinated procurement Source: Image from iStock.com

  5. Content of the 1st edition of the EDL • Published in May 2018 Sub-section a Sub-section b General IVDs Disease Specific IVDs • Organised by Disease: • HBV • HCV • HIV • Malaria • Tuberculosis • HPV • Syphilis • Organised by Discipline: • Clinical Chemistry and Immunology • Blood Transfusion • Serology • Microbiology, Mycology and Parasitology • Haematology Section I Primary Care (No lab available) Section II Facilities with Laboratories

  6. What to expect after the 1st Edition of the EDL • WHO is currently reviewing submissions for the 2nd Edition of the EDL • Submission highlights include: • A set of cancer IVDs including a new anatomical pathology section in the general IVDs • Expanding sexually transmitted infection testing • Outbreak associated IVDs such as Dengue Fever and Zika Virus, • The next SAGE IVD meeting will be in March 2019 • The second edition of the EDL will be published in May 2019 • An IVD and laboratory web portal has been launched which provides access to all IVD-related documents from WHO • WHO is planning a guidance document to support country implementation

  7. The need to implement the EDL • Ultimately, effective medical practice relies on diagnostic capabilities • The EDL is only a list until it is adopted by countries to support access to in vitro diagnostics • WHO welcomes your collaboration Source: Image from iStock.com

  8. GraciasThank you MerciShokranXiexieSpasiva WHO 20, Avenue Appia1211 Geneva Switzerland EDL Secretariat Email: edlsecretariat@who.int EDL website: http://www.who.int/medical_devices/diagnostics/Selection_in-vitro_diagnostics/en/

More Related